

Docket No.: NBI-139CP
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Francine Gervais *et al.*

Application No.: 10/728,028

Confirmation No.: 8334

Filed: December 3, 2003

Art Unit: 1618

For: AMYLOID TARGETING IMAGING
AGENTS AND USES THEREOF

Examiner: J. R. Samala

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

For the Examiner's convenience in reviewing this continuation application, Applicants submit a consolidated PTO Form SB/08, listing all references cited during the prosecution of the parent application. The present application is a Continuation-in-Part of U.S. Serial No. 09/915,092, filed July 24, 2001 (Atty. Docket No. NBI-139). All references listed on the enclosed PTO Form SB/08 have been previously cited by or submitted to the Office in the prior

application, and, in accordance with 37 CFR §1.98(d), copies of the references are not enclosed but will be provided upon request.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is “prior art” for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. NBI-139CP.

Dated: July 9, 2007

DLH/AJW/mch

Respectfully submitted,

By _____/DLH/_____
Danielle L. Herritt
Registration No.: 43,670
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant